Kainos Medicine (Novel IRAK4 Inhibitor) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Kainos Medicine (Novel IRAK4 Inhibitor) General Information

Description

A drug technology intended to cure cancers including leukemia, lymphoma and solid tumors.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Soengnam
  • South Korea
Primary Industry
Buildings and Property
Other Industries
Drug Discovery
Acquirer
Emmaus Life Sciences
Corporate Office
  • Soengnam
  • South Korea

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kainos Medicine (Novel IRAK4 Inhibitor) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Kainos Medicine (Novel IRAK4 Inhibitor)‘s full profile, request access.

Request a free trial

Kainos Medicine (Novel IRAK4 Inhibitor) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Kainos Medicine (Novel IRAK4 Inhibitor)‘s full profile, request access.

Request a free trial

Kainos Medicine (Novel IRAK4 Inhibitor) FAQs

  • Where is Kainos Medicine (Novel IRAK4 Inhibitor) headquartered?

    Kainos Medicine (Novel IRAK4 Inhibitor) is headquartered in Soengnam, South Korea.

  • What industry is Kainos Medicine (Novel IRAK4 Inhibitor) in?

    Kainos Medicine (Novel IRAK4 Inhibitor)’s primary industry is Buildings and Property.

  • Is Kainos Medicine (Novel IRAK4 Inhibitor) a private or public company?

    Kainos Medicine (Novel IRAK4 Inhibitor) is a Private company.

  • What is Kainos Medicine (Novel IRAK4 Inhibitor)’s current revenue?

    The current revenue for Kainos Medicine (Novel IRAK4 Inhibitor) is .

  • Who are Kainos Medicine (Novel IRAK4 Inhibitor)’s investors?

    Kainos Medicine has invested in Kainos Medicine (Novel IRAK4 Inhibitor).

  • When was Kainos Medicine (Novel IRAK4 Inhibitor) acquired?

    Kainos Medicine (Novel IRAK4 Inhibitor) was acquired on 12-Oct-2021.

  • Who acquired Kainos Medicine (Novel IRAK4 Inhibitor)?

    Kainos Medicine (Novel IRAK4 Inhibitor) was acquired by Emmaus Life Sciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process